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Abstract
Merkel cell carcinoma (MCC) is a rare but aggressive cutaneous neuroendocrine tumor, which multifactorial
etiopathogenesis seems to be related to ultraviolet radiation, Merkel cell polyomavirus (MCV), and immunosuppression.
In this paper, we present three cases of diagnosed MCC in apparently healthy Caucasians, two of them located in a
sun-exposed area. They represented 0.25 % of all cutaneous malignant tumors diagnosed in our department. In the
first case, MCC was diagnosed in the frontal region of a 67-year-old male, the second case was located in the right
thigh of a 55-year-old female, whereas the third case involved the upper trunk of a 62-year-old female. All of these
cases were diagnosed in the pT1 stage, having a diameter smaller than 2 cm, but the invasion depth involved the
hypodermis. Microscopically, they consisted of small cells with round-oval nuclei having finely dispersed chromatin
and well-defined nucleoli. Immunohistochemically, the tumor cells displayed positivity for keratin 20 and
neuroendocrine markers, being negative for keratin 7 and S100 protein. Maspin immunoreactivity was seen in
cases 1 and 3. Not one of the cases expressed DOG-1 or even TTF-1. Furthermore, this is the first report in
literature about maspin positivity in MCC that might be related to sun exposure.
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Background
Merkel cell carcinoma (MCC) is a cutaneous neuroendo-
crine tumor firstly described by Toker Cyril in 1972 as
trabecular carcinoma of sweat glands [1]. It mainly occurs
on sun-exposed skin, especially in the head and neck area,
followed by the extremities and trunk [2]. MCC is consid-
ered a rare but highly malignant tumor, being 40 times
less common than malignant melanoma, with a 3-year
mortality rate of 30 % and 27-61.5 % at 5-years, respect-
ively, which is much lower compared to melanomas [2–5].
In a review published in June 2001, it was mentioned
that only 836 cases of MCC have been reported in litera-
ture [6]. However, the incidence of MCC is significantly
increasing, from 0.15 cases per 100,000 in 1986 to 0.44
in 2001 and to 0.6 cases per 100,000 in 2010 [7, 8]. The
estimated annual percentage of change is about 8 % [7],
with a tripling in the rate every 15 years [3]. MCC inci-
dence in whites is 8 times higher than in blacks and
almost double the incidence in other ethnic groups.
MCC commonly affects men in all ethnic groups; the
male:female ratio being about 1.5–2:1 [4, 9]. In the 9th
period of age, the incidence increases till 4.28 cases per
100,000 [7]. Compared with healthy people, the overall
risk of MCC increases 5–23.8 times after solid organ
transplantation [10] and 11 times in patients with AIDS,
respectively [11]. However, even in the large diagnostic
centers, only 3–5 cases of MCCs per year are diag-
nosed, and most of these cases are published as case
reports. Early diagnosis is important, a routine skin
screening being recently proposed for non-melanoma
skin cancers [12].
Although ultraviolet radiation, immunosuppression, and
Merkel cell polyomavirus (MCV) infection are considered
the main factors responsible for carcinogenesis of MCC
[5, 13], the molecular mechanism is poorly understood,
and the neuroendocrine arhitecture makes the differential
diagnosis very difficult. In this paper, we report the patho-
logic findings, criteria for differential diagnosis, and the
particularities of the immunoprofile of MCCs, based on
three cases and a comprehensive literature review. A
hypothesis about the possible role of maspin in carcino-
genesis of MCC was also postulated first time in literature.
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The disease stage was evaluated based on the 2010 AJCC
TNM classification [14]. In all of the cases, a signed
informed consent of the patients was obtained for per-
forming surgery and publication of the case-related data.
Case presentation
To select the cases, a database of 3,410 consecutive
cutaneous tumors was evaluated. From these, 1,196 were
malignant tumors, and the other 2,214 being benign tu-
mors or pseudotumors. Only 3 out of 1,196 cutaneous
malignant tumors were diagnosed as MCCs (0.25 %).
Case 1
A 67-year-old previously healthy white male was hospital-
ized with a slowly growing 17×17×8 mm nodular ulcerated
tumor located on the frontal region that was surgically
removed, with free resection margins. Microscopically, the
tumor consisted of nests of small round cells with scanty
cytoplasm and round-oval nuclei with finely dispersed
chromatin and well defined nucleoli (Fig. 1). Nuclear pleo-
morphism was moderate with a high mitotic rate (>10/10
HPF). The tumor cells infiltrated the whole dermis and
subcutaneous adipose tissue, and the maximum thickness
was of 8 mm. Based on the tumor size, histological aspect,
immunoprofile (Table 1), and absence of lymph node
metastases, the tumor was diagnosed as pT1N0-stage
MCC. Nuclear maspin positivity (Fig. 2) was unexpected.
With any postoperative therapy, the patient is still
alive without any recurrences or metastases at two years
of follow-up.
Case 2
A 55-year-old previously healthy white female presented a
10×10×5 mm nodular, non-ulcerated skin tumor located
on the right thigh. Surgical excision was performed. The
microscopical aspect was similar to those described in
Case 1, but the nuclear pleomorphism was moderate, the
mitotic rate was of 8 mitoses/10 HPF, and tumor cells
were negative for Maspin. The whole dermis and subcuta-
neous adipose tissue were involved, the maximum thick-
ness was 5 mm, and all of the resection margins were
infiltrated. The histological aspect and immunoprofile
suggested a primary MCC (Table 1). The final diagnosis
was pT1-staged MCC. No lymph nodes were excised. The
patient did not come back for further therapy and is alive
at one month after surgery.
Case 3
A 62-year-old female presented a 12×12×12 mm nodular
non-ulcerated tumor of the upper trunk (sun-exposed
area) that was surgically removed. The tumor nests dis-
played the same microscopically features as in the other
two cases, the dermis and subcutaneous adipose tissue
was infiltrated and the maximum thickness was of 12 mm.
Minimal pleomorphism and <3 mitoses/10 HPF were
noted. Because the deep and lateral resection margins
were infiltrated by the tumor cells, a re-excision was
necessary. The final diagnosis, after re-excision, was
pT1-stage MCC that was confirmed by the tumor cells
immunoprofile (Table 1). The margins were found to be
microscopically uninvolved by carcinoma. Distance of car-
cinoma from closest margin: 2/2/2 mm (Peripheral
Margins and Deep Margin). Unusual nuclear maspin posi-
tivity was observed in the tumor cells. No lymph nodes
were excised and no recurrences or metastases were re-
ported six months after surgery. In addition, no radiother-
apy was performed.
Fig. 1 Microscopically, the Merkel cell carcinoma is characterized by intradermal proliferation of clusters of small cells (a, b) that are marked by
keratin 20 (c, d), epithelial membrane antigen (e), the neuroendocrine markers (f-i), CD99 (j), and bcl-2 (k) (Chr = chromogranin; EMA = epithelial
membrane antigen; NSE = neuron specific enolase; Syn = synaptophysin)
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In all three cases there was no association with condi-
tions indicating impaired immune status (organ transplant-
ation, including renal, cardiac, as well as bone marrow,
receiving immunosuppressive therapy for rheumatoid
arthritis and with aplastic anemia or lymphoma, HIV
infection, chronic lymphocytic leukemia, arsenic ingestion,
tumor after radiation therapy).
Discussion
MCC preponderantly produces early metastases in re-
gional and/or distant lymph nodes. Most of the cases
(53 %) are diagnosed in stage III with metastases in more
than 4 lymph nodes, and only 13 % of them being identi-
fied in stage I [3], such in our cases. About 20–30 % of
MCCs are diagnosed with distant metastases [15, 16]. The
5-year survival rate depends on the tumor size, ranging
from 66–75 % in tumors smaller than 2 cm to 50–60 %
in those larger than 2 cm. Positive margins, absence of
postoperative radio-chemotherapy, patient’s age (older than
75 years), relapses, and metastases are also considered im-
portant prognostic factors [3, 15–17]. The 5-year survival
rate decreases from 42–52 % in node-positive MCCs to
17–18 % in cases with distant metastases [18]. In every
non-metastatic case (stages I and II), wide excision with
safety limits and sentinel lymph node biopsy is recom-
mended, followed by radiotherapy [13]. In node-positive
MCCs (stage III), treatment of the nodal basin with lymph-
adenectomy and radiotherapy should be performed [16]. In
cases with distant metastases (stage IV), platinum-based
chemotherapy and/or immunotherapy should be asso-
ciated [16]. Oblimersem sodium can be used in bcl-2
positive cases or lorvotuzamab mertansine in CD56-
positive MCCs, but the results are not very well known
[16]. The newest drug proposed to be used for patients
Table 1 Clinicopathological features of Merkel cell carcinoma
Case no Age
(years)




Positive IHC markers Negative IHC markers
1 67 Frontal
region








Vimentin, Keratin 7, S-100












Vimentin, Keratin 7, S-100
protein, desmin, CEA,













Vimentin, Keratin 7, S-100
protein, desmin, CEA,
CD20, CD3, DOG-1, HMB45,
E-cadherin, CD3, CD20,
CD10, TTF-1
Abbreviations: CD cluster of differentiation, CEA carcinoembryonic antigen, EMA epithelial membrane antigen, IHC immunohistochemistry, NSE neuron specific
enolase; Maspin-mammary serine protease inhibitor, TTF thyroid transcription factor
Fig. 2 Microscopically, maspin cytoplasmic positivity can be seen in normal epithelium (a) whereas Merkel cell carcinoma cells express nuclear
expression (b)
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with metastatic MCC is the PI3K pathway inhibitor called
Idelalisib that was recently approved by the Food and Drug
Administration for application in B-cell lymphoma [19].
Diagnosis of MCC is very difficult and should be based
on the clinico-pathological parameters such as tumor lo-
cation, patient’s age (being more frequent in sun-exposed
areas and older people) correlated with the histological
neuroendocrine aspect, and absence of the contact of
tumor cells with the epidermis. In few cases epidermo-
tropism and additional divergent components such as
squamous, follicular, porocarcinoma, sarcomatous, glan-
dular, and neuroblastic were noted [5]. However, the final
diagnosis depends on the tumor profile and should take
into account a metastasis from tumors with round cells
(small cell lung carcinoma, neuroendocrine carcinoma of
other organs, neuroblastoma), other cutaneous carcin-
omas with round cells (sweat gland carcinoma, basal
cell carcinoma with neuroendocrine differentiation, small
cell squamous cell carcinoma, primary cutaneous small
cell carcinoma), lymphomas, and melanomas.
The immunohistochemical characteristics expression
of neuroendocrine markers correlated with perinuclear
dot-like positivity of keratin 20 is considered specific for
MCC [4, 20]. However, unusual immunopositivity of the
tumor cells was also reported (Table 2). The monoclonal
antibody CM2B4 marker was also introduced in 2009 in
clinical practice, which acts against a predicted antigenic
epitope on the MCV T-antigen and can be added in the
daily diagnosis panel of antibodies [20, 21]. In some of
the cases, keratin 20 can be negative, especially in carcin-
omas unrelated with MCV infection [22]. Unusual positiv-
ity was reported for markers such as TTF-1 [23], CD57,
PAX-5, TDT (terminal deoxynucleotidyl transferase) [24],
and maspin, first reported in this study.
Differentiation of MCC from cutaneous metastases of
neuroendocrine carcinoma is difficult and can be based
on CEA negativity (that is usually positive in tumors of
the gastrointestinal tract and pancreas) and inconstant
positivity for keratin 20 [5, 6]. Predominantly, TTF-1
negativity and PAX-5 positivity of MCC is a diagnostic
tool in differentiation from a metastatic lung cancer,
although inconstant positivity was also observed in MCC
[16, 23, 24]. Regarding the primary cutaneous small cell
carcinoma, this lesion is characterized by the complete
absence of nucleoli, which are well visible in MCC, and
keratin 20 negativity [25]. Moreover, the primary cutane-
ous small cell carcinomas including basal cell carcinoma
with neuroendocrine differentiation are negative for kera-
tin 20 [20, 26].
The first description of the Merkel cells was performed
in 1875 by Friedrich Sigmund Merkel, who called them
“tastzellen” or “touch cell” [27]. Further studies proved,
using the electron microscope, that they are located in the
basal layer of epidermis and dermis and play a role on
slowly adapting mechanoreceptors to sense touch and hair
movement [9, 16]. Merkel cells display a monomorphic
aspect with scanty cytoplasm and nuclei with fine chro-
matin; the MCC showing proliferation of similar cells with
nuclear pleomorphism.
The role of MCV infection was also recognized in 2008
as a predisposing factor for genesis of MCC. However, due
to the fact that MCC can arise in the background of
chronic radiodermatitis in patients negative for MCV [28]
and mostly occurs in the sun-exposed areas, supposition
that ultraviolets can induce activation, proliferation, and
malignization of some pluripotent stem cells was evolved
[16]. Also, some studies have shown that MCC with diver-
gent differentiation is an aggressive subtype, in whose
development MCV is not involved [4, 5].
In this paper, unusual nuclear maspin maspin positivity
was noted in both of the cases that occured in the sun
Table 2 Differential diagnosis of Merkel cell carcinoma based
on the tumor cells immunoprofile [2–34]
IHC marker MCC BCC with neuroendocrine
differentiation
Melanoma SCLC - skin
metastasis
AE1/AE3 Keratin + + ± +
Keratin 20 ± - - -
Keratin 7 ± - - +
EMA + + - +
CEA - - - -
Chromogranin ± ± - ±
Synaptophysin + ± - ±
NSE ± ± - ±
CD56 ± ± - +
CD99 + - - -
Bcl-2 ± - - -
S-100 protein + - + -
TTF-1 ± - - +
Vimentin - - + -
TDT ± - - ±
DOG-1 - ± - -
HMB45 - - ± -
Melan A - - + -
E-cadherin - + - -
Maspin ± ± ± ±
CD57 ± - ± ±
PAX-5 ± - - -
c-KIT ± - ± -
Abbreviations: BCC basal cell carcinoma, CD cluster of differentiation,
CEA carcinoembryonic antigen, EMA epithelial membrane antigen,
IHC immunohistochemistry, MCC Merkel cell carcinoma, NSE neuron specific
enolase; Maspin-mammary serine protease inhibitor, SCLC-small cell lung
carcinoma, TDT terminal deoxynucleotidyl transferase, TTF thyroid
transcription factor
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exposed areas (case 1 - face and case 3 - upper trunk),
without any correlation with the mitotic rate, depth of
infiltration, or the quality of the resection margins. The
normal epidermis showed a cytoplasmic positivity. How-
ever, being about first report in literature about maspin
expression in MCC, it is difficult to emit suppositions
about its role in this cutaneous tumor, further studies
being necessary to confirm its positivity in larger cohorts.
Maspin (mammary serine protease inhibitor) is a mem-
ber of the serine protease inhibitor family that is knows to
play a tumor suppressor role in several malignant epithelial
tumors such as colorectal or gastric carcinomas [29–31].
However, its prognostic role depends on the subcellular
localization, the p53-mediated nuclear positivity usually in-
dicating a more aggressive behavior, a higher risk for tumor
relapse and lymph node metastases, whereas loss of ex-
pression proved to induce a higher risk for distant metasta-
ses, at least for gastrointestinal malignant tumors [30, 31].
In tumors of the skin, maspin immunoreactivity was de-
scribed in 97 % of squamous cell carcinomas and 88 % of
basal cell carcinomas, but also in malignant melanomas,
more frequent in sun-exposed areas [32, 33]. Few than 25
papers regarding maspin expression in cutaneous tumors
have been published to date. However, there are limited
data regarding correlation of maspin immunoreactivity
with the prognosis. In squamous cell carcinomas, maspin
positivity rate was higher in early stages compared with the
advanced staged tumors (61 % vs. 39 %) and in non-
metastatic tumors compared with cases that displayed
lymph node positivity (67 % vs. 33 %). In bout squamous-
and basal cell carcinomas it was especially displayed by tu-
mors of the head and neck area (70 % vs. 30 %) [34]. A
possible sun-activated maspin-induced DNA damage was
also supposed [33]. On the other hand, nuclear expression
proved to have a tumor suppressor role in basal cell carcin-
oma [34] but indicated poorer survival in melanomas [33].
The supposition about role of maspin in carcinogen-
esis of non-melanoma skin tumors that include MCC
should be tested in further studies, on large cohorts.
Conclusion
This report shows that Maspin positivity in Merkel cell
carcinoma might be related on sun exposure.
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